Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 25Leukemia, Lymphocytic, Chronic, B-Cell 10Breast Neoplasms 10Recurrence 9Leukemia, Myeloid, Acute 9Carcinoma, Non-Small-Cell Lung 9Neuroblastoma 8Lymphoma, Non-Hodgkin 8Neoplasms 7Ovarian Neoplasms 6Neoplasm Metastasis 6Leukemia 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Uveal Melanoma 5Myelodysplastic Syndromes 5Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma 5Lung Neoplasms 5Head and Neck Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 4Hematologic Neoplasms 4Carcinoma, Squamous Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3

Interventions

Gemcitabine 170130-nm albumin-bound paclitaxel 54Albumin-Bound Paclitaxel 42Oxaliplatin 33Fluorouracil 32pembrolizumab 30Capecitabine 30Leucovorin 28Irinotecan 28Radiotherapy 25Nivolumab 22Erlotinib Hydrochloride 21Taxes 19Cisplatin 19Bevacizumab 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiosurgery 11Ipilimumab 11Cyclophosphamide 11Drug Therapy 10Carboplatin 10Biopsy 10Paclitaxel 9Docetaxel 9Cetuximab 9trametinib 8olaparib 8durvalumab 8Sorafenib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Neoplasms × Interleukin-2 × Clear all
NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡